
The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ:REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).
The regulatory agency has set a target action date of February 28, 2023.